Emerging cancer therapies and cardiovascular risk
- Resource Type
- Authors
- Eiman Jahangir; Wendy Bottinor; Amar Parikh
- Source
- Journal of Thrombosis and Thrombolysis. 51:837-845
- Subject
- Cardiovascular toxicity
medicine.medical_specialty
2019-20 coronavirus outbreak
Immune checkpoint inhibitors
medicine.medical_treatment
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Antineoplastic Agents
030204 cardiovascular system & hematology
Androgen deprivation therapy
03 medical and health sciences
0302 clinical medicine
Risk Factors
Neoplasms
medicine
Humans
030212 general & internal medicine
Cardio oncology
Intensive care medicine
business.industry
Cancer
Hematology
medicine.disease
Radiation therapy
Cardiovascular Diseases
Heart Disease Risk Factors
Cardiology and Cardiovascular Medicine
business
- Language
- ISSN
- 1573-742X
0929-5305
The cardiovascular (CV) toxicity profiles of traditional cancer therapies such as anthracyclines and radiation therapy are familiar to many cardiologists. With the development and widespread use of additional cancer therapeutics, CV toxicities related to these agents are becoming more common. Cardiovascular specialists are often integrated into the care team for individuals with cancer and knowledge of the CV toxicities of cancer therapeutics has become essential. In this review, we provide a clinically focused summary of the current data regarding CV toxicities of common cancer therapies and identify potential management strategies for the CV specialist.